Similarly, the development of thermosensitive gels, such as AC102, for intratympanic injection has shown safety and tolerability in human trials, demonstrating the feasibility of this approach for inner ear drug delivery (Lanting et al., 2025)
Exenatide-PD3, reported in The Lancet in early 2025, was the largest and longest trial of a GLP-1R agonist in Parkinsons disease: 194 patients, once-weekly exenatide, 96 weeks
High-quality synthesis and rigorous testing are critical to ensuring consistent results across studies
This balanced approach can help you transition into fasting while reaping the appetite-regulating benefits of GLP-1 treatments
A 2021 human study of 12 subjects demonstrated improved insulin sensitivity after 14 days